EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
BACKGROUND:Gastrointestinal stromal tumors (GISTs) are rare, but represent the most common mesenchymal neoplasms of the gastrointestinal tract. EPIdemiology GIST, is an observational multicenter longitudinal follow-up cohort study reporting the prescribing patterns of imatinib in patients with GIST...
Main Authors: | Olivier Bouché, Axel Le Cesne, Maria Rios, Loic Chaigneau, Antoine Italiano, Florence Duffaud, Thierry Lecomte, Dominique Arsène, Sylvain Manfredi, Thomas Aparicio, Stéphane Remy, Nicolas Isambert, Olivier Collard, Frank Priou, François Bertucci, Roland Sambuc, Ségolene Bisot-Locard, Olivier Bourges, Sylvie Chabaud, Jean-Yves Blay |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6143255?pdf=render |
Similar Items
-
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
by: Cupissol Didier, et al.
Published: (2011-02-01) -
Recent advances in managing gastrointestinal stromal tumor [version 1; referees: 2 approved]
by: Florence Duffaud, et al.
Published: (2017-09-01) -
Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal
by: F Duffaud, et al.
Published: (2010-05-01) -
Folie et modernité selon Michel Foucault et de Marcel Gauchet
by: Lecomte, Olivier
Published: (2015) -
Imatinibe mesilato no Brasil Imatinibe mesylate in Brazil
by: Marcos Lima
Published: (2005-09-01)